Lupus Science & Medicine

Papers
(The TQCC of Lupus Science & Medicine is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
2021 DORIS definition of remission in SLE: final recommendations from an international task force140
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials59
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies39
Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to ac37
Living with systemic lupus erythematosus in 2020: a European patient survey36
Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review31
Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis30
Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria30
SARS-CoV-2 vaccines in patients with SLE29
Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data28
Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis24
Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries24
Phenotypical changes and clinical significance of CD4+/CD8+T cells in SLE24
Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway23
Apolipoprotein L1 risk genotypes in Ghanaian patients with systemic lupus erythematosus: a prospective cohort study23
Herpes zoster in SLE: prevalence, incidence and risk factors23
Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis22
Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004–201522
Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis21
Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus21
LLDAS is an attainable treat-to-target goal in childhood-onset SLE21
Associations of metabolic syndrome in SLE19
Towards a practical management of fatigue in systemic lupus erythematosus19
Discoid lupus erythematosus skin lesion distribution and characteristics in Black patients: a retrospective cohort study17
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica17
Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus17
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE17
Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004–201517
Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus17
Clinical and histopathological features of myositis in systemic lupus erythematosus16
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes16
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study16
Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus16
Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus16
LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almen15
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus15
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis15
Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus15
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?14
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms14
Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial13
Infection hospitalisation in systemic lupus in Sweden13
Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre13
Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort13
Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis13
Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis12
Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus12
Absence of renal remission portends poor long-term kidney outcome in lupus nephritis12
Hospitalisation for systemic lupus erythematosus associates with an increased risk of mortality in Australian patients from 1980 to 2014: a longitudinal, population-level, data linkage, cohort study11
Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need11
Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies11
Real-world burden of systemic lupus erythematosus in the USA: a comparative cohort study from the Medical Expenditure Panel Survey (MEPS) 2016–201811
Impact of severe infections in SLE: an observational study from the Spanish national registry11
ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases11
Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state f(unctional) MRI study11
Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE10
The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research10
Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case–control study10
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme10
Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety10
LUPUS-BEST—treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial10
Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials10
Characteristics of cardiovascular autonomic dysfunction and association with quality of life in patients with systemic lupus erythematosus10
The Care-coordination Approach to Learning Lupus Self-Management: a patient navigator intervention for systemic lupus inpatients10
Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)10
Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus10
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial10
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis10
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study9
Breastfeeding in women with rheumatic diseases9
Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives9
Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort9
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials9
Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis9
Anti-Müllerian hormone in African-American women with systemic lupus erythematosus8
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks8
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine8
Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis8
RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin8
Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study8
Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus8
Central nervous system infections in patients with systemic lupus erythematosus: a systematic review and meta-analysis8
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial8
Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence8
Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE8
One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria8
Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome8
Infertility in systemic lupus erythematosus: what rheumatologists need to know in a new age of assisted reproductive technology8
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE8
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE8
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up8
Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic scler8
0.031915187835693